219 individuals tested positive for the antibodies, with seroprevalence increasing from 5% to 11% over the course of the 5-week study. The authors estimated an overall seroprevalence in the general population of Geneva using a Bayesian logistic regression model to be 4.8% (95% CI 2.4-8.0) the first week, 8.5% (95% CI 5.9-11.4) the second, 10.9% (95% CI 7.9-14.4) the third, 6.6% (95% CI 4.3-9.4) the fourth, and 10.8% (95% CI 8.2-13.9) the fifth.

Seroprevalence among the subset from the Bus Sante study revealed similar RR estimates for 65+ and across genders in this study. When the authors ran the confirmatory test, they found their estimates were very relatively unchanged.